Foamix Pharmaceuticals Ltd.
SEC CIK 1606645 · FOMX · last insider filing 2020-03-18
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Stern Stanley | Director | filed 2018 - 2020 |
| Barbari Sharon Surrey | Director | filed 2019 - 2020 |
| Bright Rex | Director | filed 2018 - 2020 |
| Kazanchyan Anna | Director | filed 2018 - 2020 |
| Bruno Anthony D | Director | filed 2018 - 2020 |
| Schwartz Aharon | Director | filed 2018 - 2020 |
| Domzalski David | Director · CEO | filed 2018 - 2020 |
| Hirsch Stanley | Director | filed 2018 - 2020 |
| Rigel Darrell S | Director | filed 2018 - 2018 |
| Megiddo Dalia | Director | filed 2018 - 2018 |
| Tamarkin Dov | Director | filed 2018 - 2018 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Hadar Ilan | Country Manager and CFO | filed 2018 - 2020 |
| Stuart Iain | SVP R&D | filed 2018 - 2020 |
| Harsch Mutya | General Counsel and SVP Legal | filed 2018 - 2020 |
| Wiley Matthew T. | Chief Commercial Officer | filed 2018 - 2020 |
| Howard Alvin D | VP Regulatory | filed 2018 - 2018 |
| Elliott Russell P. | VP Drug Development | filed 2018 - 2018 |
| Hazot Yohan | VP Pharmaceutical Development | filed 2018 - 2018 |
| Schuz David | VP Intellectual Property | filed 2018 - 2018 |
| Shirvan Mitchell | VP Innovation & Discovery | filed 2018 - 2018 |
| Pappacena Bonnie | VP Quality | filed 2018 - 2018 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.